Hologic Inc (HOLX) Stock Price, Quote & News

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, an...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 508 263 2900

Website: www.hologic.com

Address:

250 Campus Drive, Marlborough, United States

ZacksResearch Aug. 20 at 1:16 PM

Is $HOLX underappreciated in the cytology space? 💡 Despite a 5.2% gain over six months, Hologic is trading at a forward P/E of 15.23X, well below the industry average of 28.67X. Its Genius digital cytology system is poised to drive future growth, especially as it addresses labor shortages and infrastructure limitations globally. Discover if HOLX is a hidden gem in healthcare 👉 https://www.zacks.com/stock/news/2739809/whats-behind-hologics-positive-long-term-outlook-for-cytology-unit?cid=sm-stocktwits-2-2739809-body-8547&ADID=SYND_STOCKTWITS_TWEET_2_2739809_BODY_8547

0 · Reply

ZacksResearch Aug. 20 at 12:16 PM

$HOLX long-term bull case? 👀 The company’s Cytology unit is showing a positive outlook, pointing to sustained strength ahead. See the full breakdown of what’s driving the optimism 👉 https://www.zacks.com/stock/news/2739809/whats-behind-hologics-positive-long-term-outlook-for-cytology-unit?cid=sm-stocktwits-2-2739809-teaser-8524&ADID=SYND_STOCKTWITS_TWEET_2_2739809_TEASER_8524

0 · Reply

ZacksResearch Aug. 13 at 12:51 PM

$HOLX poised for growth — is it time to hold? 🚀 Hologic's Breast Health division is showing sequential improvement, with 3D gantry shipments up compared to the prior quarter and new leadership driving sales focus. Plus, HOLX trades at a forward P/E of 15.28X, well below the industry average of 28.00X. See why HOLX could be a promising investment 👉 https://www.zacks.com/stock/news/2706735/hologic-eyes-organic-growth-rebound-in-2026-on-breast-health-strength?cid=sm-stocktwits-2-2706735-body-7573&ADID=SYND_STOCKTWITS_TWEET_2_2706735_BODY_7573

0 · Reply

ZacksResearch Aug. 13 at 11:51 AM

$HOLX targeting a growth comeback in 2026 📈 The company sees a rebound in organic growth driven by strong performance in Breast Health. Full outlook here 👉 https://www.zacks.com/stock/news/2706735/hologic-eyes-organic-growth-rebound-in-2026-on-breast-health-strength?cid=sm-stocktwits-2-2706735-teaser-7562&ADID=SYND_STOCKTWITS_TWEET_2_2706735_TEASER_7562

0 · Reply

ZacksResearch Aug. 8 at 1:20 PM

$HOLX: Diagnostics unit faces headwinds, but growth drivers remain strong! 🚀 Despite geopolitical challenges, the Diagnostics segment posted just 0.9% YoY growth, with support from BV, CV/TV assays, and Panther Fusion. Innovative strides with Biotheranostics in oncology add to future potential. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2683571/hologics-diagnostics-arm-set-for-long-term-upside-whats-behind-it?cid=sm-stocktwits-2-2683571-body-6826&ADID=SYND_STOCKTWITS_TWEET_2_2683571_BODY_6826

0 · Reply

ZacksResearch Aug. 8 at 12:08 PM

$HOLX could have a sleeper growth engine brewing 📈 The Diagnostics segment is positioned for sustained gains, with growth drivers that could power upside well beyond the near term. Full breakdown of the long-term setup here 👉 https://www.zacks.com/stock/news/2683571/hologics-diagnostics-arm-set-for-long-term-upside-whats-behind-it?cid=sm-stocktwits-2-2683571-teaser-6792&ADID=SYND_STOCKTWITS_TWEET_2_2683571_TEASER_6792

0 · Reply

StockAutoPro Aug. 6 at 4:14 PM

$HOLX: Buy target $65.81 Sell target $71.2 Strong pipeline of innovative products could boost this healthcare company's growth in the long term.

0 · Reply

ZacksResearch Aug. 6 at 2:18 PM

$HOLX Q3 results: outperforming expectations! 🚀 Hologic's Molecular Diagnostics sales climbed 7.3% in the U.S., and Interventional sales surged 31.8%. With a strong balance sheet and raised 2025 guidance, shares have climbed 4.4% since the report. Discover the full breakdown on Hologic's performance and outlook here 👉 https://www.zacks.com/stock/news/2672340/should-you-buy-sell-or-hold-hologic-stock-post-q3-earnings?cid=sm-stocktwits-2-2672340-body-6288&ADID=SYND_STOCKTWITS_TWEET_2_2672340_BODY_6288

0 · Reply

ZacksResearch Aug. 6 at 11:56 AM

$HOLX just posted Q3 earnings — time to buy, sell, or hold? The company beat the Zacks Consensus Estimate for earnings but missed on revenue, and guidance was mixed. Full breakdown here 👉 https://www.zacks.com/stock/news/2672340/should-you-buy-sell-or-hold-hologic-stock-post-q3-earnings?cid=sm-stocktwits-2-2672340-teaser-6205&ADID=SYND_STOCKTWITS_TWEET_2_2672340_TEASER_6205

0 · Reply

scientificway Aug. 3 at 4:24 AM

$HOLX check MDXG out, huge guidance up

0 · Reply

Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript

Jul 30, 2025, 6:06 PM EDT - 23 days ago

Hologic raises annual profit forecast on diagnostic and surgical demand

Jul 30, 2025, 4:01 PM EDT - 23 days ago

Hologic Announces Financial Results for Third Quarter of Fiscal 2025

Jul 22, 2025, 5:06 PM EDT - 4 weeks ago

Hologic Q3 Preview: Tariff Pressure And Undervalued Stock Price, Initiate With Buy

Jul 2, 2025, 4:05 PM EDT - 7 weeks ago

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

Jun 2, 2025, 11:03 AM EDT - 2 months ago

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation

May 27, 2025, 3:48 PM EDT - 3 months ago

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

May 27, 2025, 1:05 PM EDT - 3 months ago

Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports

BX TPG

May 22, 2025, 5:05 PM EDT - 3 months ago

Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

May 13, 2025, 4:10 PM EDT - 3 months ago

Hologic to Webcast Presentations at Upcoming Investor Conferences

May 6, 2025, 5:39 PM EDT - 3 months ago

Hologic: Soft Performance, But Cheap Enough

May 1, 2025, 8:24 PM EDT - 4 months ago

Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript

May 1, 2025, 6:58 PM EDT - 4 months ago

Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty

May 1, 2025, 4:01 PM EDT - 4 months ago

Hologic Announces Financial Results for Second Quarter of Fiscal 2025

Apr 25, 2025, 4:25 AM EDT - 4 months ago

Cellulite Treatment Market Trends, Growth Opportunities and Shares 2025-2030; Featuring Key Players - Hologic (Cynosure), Merz Pharma, Syneron Medical, Zimmer Aesthetics & More

Apr 24, 2025, 8:10 AM EDT - 4 months ago

Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI

Apr 22, 2025, 8:08 AM EDT - 4 months ago

Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report

Apr 4, 2025, 4:15 PM EDT - 5 months ago

Wayde McMillan Elected to Hologic Board of Directors

Apr 3, 2025, 4:30 PM EDT - 5 months ago

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025

Feb 25, 2025, 8:15 AM EST - 6 months ago

Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference

Feb 20, 2025, 3:00 AM EST - 6 months ago

Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software

Feb 18, 2025, 8:08 AM EST - 6 months ago

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Feb 5, 2025, 10:06 PM EST - 7 months ago

Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 5:56 PM EST - 7 months ago

Hologic cuts annual revenue forecast on weak demand for breast health products

Feb 5, 2025, 4:01 PM EST - 7 months ago

Hologic Announces Financial Results for First Quarter of Fiscal 2025

Jan 21, 2025, 8:00 AM EST - 7 months ago

New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide

Jan 17, 2025, 1:28 PM EST - 7 months ago

Hologic: Reasonably, But Not Compellingly Valued

Jan 12, 2025, 4:00 PM EST - 7 months ago

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

Jan 7, 2025, 4:04 PM EST - 8 months ago

Hologic to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:15 PM EST - 8 months ago

Hologic to Announce Financial Results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025

Jan 6, 2025, 8:05 AM EST - 8 months ago

Hologic Completes Acquisition of Gynesonics, Inc.

Jan 3, 2025, 12:06 PM EST - 8 months ago

Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz

ABT BMY LLY NVO UNH XBI XLV

Dec 18, 2024, 8:08 AM EST - 8 months ago

Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC

Dec 10, 2024, 4:01 PM EST - 9 months ago

Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines

Dec 9, 2024, 4:05 PM EST - 9 months ago

Martin Madaus Elected to Hologic Board of Directors

Dec 9, 2024, 8:05 AM EST - 9 months ago

New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence

Dec 2, 2024, 8:08 AM EST - 9 months ago

Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations

Nov 25, 2024, 8:22 AM EST - 9 months ago

Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024

Nov 4, 2024, 7:26 PM EST - 10 months ago

Hologic, Inc. (HOLX) Q4 2024 Earnings Call Transcript

Nov 4, 2024, 4:01 PM EST - 10 months ago

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024

Oct 19, 2024, 2:00 PM EDT - 10 months ago

Hologic to acquire Gynesonics in $350M deal to boost Fibroid treatments

Oct 14, 2024, 2:07 PM EDT - 11 months ago

Hologic Adds Gynesonics' Sonata System In $350M Acquisition To Boost Fibroid Treatments

Oct 14, 2024, 8:05 AM EDT - 11 months ago

Hologic to Acquire Gynesonics, Developer of Minimally Invasive Solutions for Women's Health

Oct 4, 2024, 8:22 AM EDT - 11 months ago

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2024 on Monday, November 4, 2024

Oct 1, 2024, 9:12 AM EDT - 11 months ago

Hologic CEO Steve MacMillan on breast cancer detection, future of AI-powered diagnostics

Sep 30, 2024, 9:17 AM EDT - 11 months ago

Hologic Unveils #BustTheMyth Campaign to Debunk Breast Cancer Myths and Empower Women This Breast Cancer Awareness Month

Aug 29, 2024, 8:08 AM EDT - 1 year ago

Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference

Jul 30, 2024, 12:50 PM EDT - 1 year ago

Hologic CEO on earnings beat: our Covid work has 'turbocharged' diagnostics business

Jul 30, 2024, 9:05 AM EDT - 1 year ago

Hologic Analysts Boost Their Forecasts After Q3 Results

Jul 29, 2024, 8:40 PM EDT - 1 year ago

Hologic, Inc. (HOLX) Q3 2024 Earnings Call Transcript

ZacksResearch Aug. 20 at 1:16 PM

0 · Reply

ZacksResearch Aug. 20 at 12:16 PM

0 · Reply

ZacksResearch Aug. 13 at 12:51 PM

0 · Reply

ZacksResearch Aug. 13 at 11:51 AM

0 · Reply

ZacksResearch Aug. 8 at 1:20 PM

0 · Reply

ZacksResearch Aug. 8 at 12:08 PM

0 · Reply

StockAutoPro Aug. 6 at 4:14 PM

$HOLX: Buy target $65.81 Sell target $71.2 Strong pipeline of innovative products could boost this healthcare company's growth in the long term.

0 · Reply

ZacksResearch Aug. 6 at 2:18 PM

0 · Reply

ZacksResearch Aug. 6 at 11:56 AM

0 · Reply

scientificway Aug. 3 at 4:24 AM

$HOLX check MDXG out, huge guidance up

0 · Reply

IN0V8 Aug. 1 at 6:29 PM

$HOLX Mizuho raises target price to $75 from $70 Morgan Stanley raises target price to $69.00 from $65.00

0 · Reply

Fiolek Aug. 1 at 9:29 AM

$HOLX

0 · Reply

Thestocktraderhubzee Jul. 31 at 3:29 PM

$HOLX Morgan Stanley Maintains Equal-Weight on Hologic, Raises Price Target to $69

0 · Reply

JarvisFlow Jul. 31 at 3:29 PM

Morgan Stanley has updated their rating for Hologic ( $HOLX ) to Equal-Weight with a price target of 69.

0 · Reply

ZacksResearch Jul. 31 at 1:09 PM

$HOLX beats earnings but shares slip 0.7% in after-hours trading! 📉 Adjusted EPS of $1.08 beat estimates by 2.86%, and revenues climbed 1.2% year over year. Yet, U.S. revenues fell 0.6%, gross and operating margins contracted, and challenges in China and Africa loom over Diagnostics. Full breakdown here 👉 https://www.zacks.com/stock/news/2643105/hologic-stock-falls-despite-q3-earnings-and-revenue-beat-margins-down?cid=sm-stocktwits-2-2643105-body-4932&ADID=SYND_STOCKTWITS_TWEET_2_2643105_BODY_4932

0 · Reply

ZacksResearch Jul. 31 at 11:37 AM

$HOLX beats on both earnings and revenues… so why’s the stock dropping? Margins took a hit in Q3 — that’s what’s weighing on the reaction. Full breakdown here 👉 https://www.zacks.com/stock/news/2643105/hologic-stock-falls-despite-q3-earnings-and-revenue-beat-margins-down?cid=sm-stocktwits-2-2643105-teaser-4920&ADID=SYND_STOCKTWITS_TWEET_2_2643105_TEASER_4920

0 · Reply

DonCorleone77 Jul. 30 at 9:06 PM

$HOLX Hologic reports Q3 adjusted EPS $1.08, consensus $1.05 -- Reports Q3 revenue $1.023B, consensus $1.01B. -- Sees Q4 adjusted EPS $1.09-$1.12, consensus $1.07 -- Sees Q4 revenue $1.03B-$1.04B, consensus $1.03B. -- Raises FY25 EPS view to $4.23-$4.26 from $4.15-$4.25, consensus $4.18 -- Narrows FY25 revenue view to $4.081B-$4.091B from $4.05B-$4.1B, consensus $4.07B.

0 · Reply

healthcareguru Jul. 30 at 8:34 PM

$HOLX JUNK qtr, low quality beat from non-core segment…going right back down.

0 · Reply

ZacksResearch Jul. 29 at 1:01 PM

$HOLX struggles in Breast Health — but is a turnaround on the horizon? 📉 Despite HOLX shares declining 20.4% over the past year and a bearish EPS trend, Hologic expects a Q4 rebound for its Breast Health unit. Plus, service revenues rose 12% YoY in the second quarter, offering some stability. See if HOLX's strategy can lift its Zacks Rank #4 (Sell) stock 👉 https://www.zacks.com/stock/news/2633047/hologic-focuses-on-breast-health-turnaround-this-year-can-it-deliver?cid=sm-stocktwits-2-2633047-body-4372&ADID=SYND_STOCKTWITS_TWEET_2_2633047_BODY_4372

0 · Reply

ZacksResearch Jul. 29 at 11:40 AM

$HOLX is betting big on a breast health rebound — but can it execute? Management is prioritizing a turnaround in its Breast Health business in 2025, aiming to revive one of its core segments. Full breakdown of the plan and potential here 👉 https://www.zacks.com/stock/news/2633047/hologic-focuses-on-breast-health-turnaround-this-year-can-it-deliver?cid=sm-stocktwits-2-2633047-teaser-4354&ADID=SYND_STOCKTWITS_TWEET_2_2633047_TEASER_4354

0 · Reply

John_Wick1234 Jul. 28 at 11:11 AM

$HOLX Price Cross above 200 EMA.

0 · Reply

ZacksResearch Jul. 25 at 2:13 PM

$EXAS vs. $HOLX — Why Exact Sciences might be the smarter choice right now! 🔍 📈 Exact Sciences is riding high on Cologuard adoption with a bullish Zacks Rank #2 (Buy) and EPS estimates showing a 169.6% improvement for 2025. 📉 Meanwhile, Hologic's facing tariff pressures, softer demand, and a Zacks Rank #4 (Sell). Find out why EXAS could outperform HOLX 👉 https://www.zacks.com/stock/news/2616843/holx-vs-exas-which-cancer-diagnostics-stock-should-you-retain-now?cid=sm-stocktwits-2-2616843-body-3886&ADID=SYND_STOCKTWITS_TWEET_2_2616843_BODY_3886

0 · Reply

Market Cap	14.94B
Revenue (ttm)	4.03B
Net Income (ttm)	789.50M
EPS (ttm)	N/A
PE Ratio	16.57
Forward PE	16.23
Profit Margin	19.59%
Debt to Equity Ratio	0.52

Volume	1,545,900
Avg Vol	2,043,814
Day's Range	N/A - N/A
Shares Out	222.42M
Stochastic %K	65%
Beta	0.49
Analysts	Sell
Price Target	$73.94